FDA Drug Safety Podcasts

FDA Drug Safety Podcasts

U.S. Food and Drug Administration, Center for Drug Evaluation and ResearchU.S. Food and Drug Administration, Center for Drug Evaluation and Research
Release Date

All Episodes

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) 

 . 4min 0sec
FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns

Listen to an audio podcast of the 6/1/22 for Ukoniq . FDA withdrew its approval for the cancer medicine Ukoniq (active ingredient umbralisib) due to safety concerns. Ukoniq was approved to treat two specific types of lymphoma: marginal zone lymphoma (MZL) and follicular lymphoma ...  Show more

 . 2min 0sec
FDA recommends thyroid monitoring in babies and young children who receive injections of iodine-containing contrast media for medical imaging

Listen to an audio podcast of the March 30, 2022 FDA Drug Safety Communication Iodinated Contrast Media 

 . 4min 30sec
FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)

Listen to an audio podcast of the February 3, 2022, FDA Drug Safety Communication, FDA is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib). We are re-evaluating this risk against the benefits of Ukoniq for its approved uses. 

 . 3min 30sec
FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain

Listen to an audio podcast of the January 12, 2022, FDA Drug Safety Communication warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the mouth. 

 . 5min 59sec